Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Vaxcyte, Inc. PCVX

Set alert

Price alert · PCVX

All alert types
60.62 USD 0.00 0.00%

At close

60.62 0.00 0.00%

Pre-market · Nov 3, 9:13 AM ET

Bid
60.58 × 2
Ask
60.62 × 2

Day range unavailable

39.87 52-week range 90.75
YTD
+31.38%
1 year
+33.88%
Open
—
Prev close
60.62
Mkt cap
9.54B
Vol
0
Avg vol
2.09M
EPS
-7.62
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-8.52
Beta
1.29
Short ratio
4.40
Inst. own
111.07%
Dividend
0.00
Ex-div date
Earnings
Nov 3, 2026
50-d avg
61.60
200-d avg
57.04
1y target
117.30

YTD chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Feb 24, 2026Earnings: -1.8; estimate -1.52973; surprise -17.67%
  • May 6, 2026Earnings: -2.3; estimate -1.7775; surprise -29.4%
  • Aug 5, 2026Earnings: -1.97; estimate -2.06; surprise 4.37%
  • Sep 25, 2026Rating: Needham · Buy → Buy
  • Sep 28, 2026Rating: B of A Securities · Buy → Buy
  • Oct 5, 2026Rating: Guggenheim · Buy → Buy
  • Oct 5, 2026Rating: Needham · Buy → Buy
  • Oct 5, 2026Rating: BTIG · Buy → Buy
  • Oct 12, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
Signals (49)
NameDateAgo
SMA: BearishNov 2, 202623 hours ago
SMA: BullishOct 29, 20265 days ago
SMA: BearishOct 23, 20261 week ago
MACD: Sell SignalOct 19, 20262 weeks ago
SMA: BullishOct 5, 20264 weeks ago
MACD: Buy SignalOct 5, 20264 weeks ago
RSI: OverboughtOct 5, 20264 weeks ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BearishSep 18, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
MACD: Sell SignalJul 15, 20263 months ago
RSI: OverboughtJun 30, 20264 months ago
SMA: BullishJun 24, 20264 months ago
SMA: BullishJun 15, 20264 months ago
MACD: Buy SignalJun 11, 20264 months ago
MACD: Sell SignalJun 8, 20264 months ago
SMA: BearishJun 5, 20265 months ago
SMA: BullishJun 4, 20265 months ago

Newest 20 of 49.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 117.30 +93.5% upside
Target (low)
75.00
Target (mean)
117.30
Target (high)
163.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy9
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 11
  • 1 month ago 11
  • 2 months ago 11

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PCVX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-2.11-2.68 – -1.67-1.56-35.3%00.0%7
Next quarter-1.96-2.69 – -0.86-1.80-9.0%00.0%7
Current year-8.14-9.66 – -6.19-5.63-44.6%00.0%7
Next year-7.12-11.42 – -4.96-8.14+12.6%87.15M0.0%7

Upgrades and downgrades

The latest rating changes

PCVX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026Cantor FitzgeraldReiteratedOverweightOverweight
Oct 5, 2026BTIGReiteratedBuyBuy
Oct 5, 2026NeedhamMaintainedBuyBuy
Oct 5, 2026GuggenheimMaintainedBuyBuy
Sep 28, 2026B of A SecuritiesMaintainedBuyBuy
Sep 25, 2026NeedhamReiteratedBuyBuy
Feb 26, 2026BTIGMaintainedBuyBuy
Feb 2, 2026GuggenheimReiteratedBuyBuy
Nov 10, 2025BTIGReiteratedBuyBuy
Oct 16, 2025BTIGMaintainedBuyBuy
Sep 12, 2025Goldman SachsInitiated—Neutral
Apr 22, 2025Cantor FitzgeraldInitiated—Overweight
Apr 8, 2025NeedhamReiteratedBuyBuy
Apr 1, 2025Goldman SachsMaintainedBuyBuy
Apr 1, 2025B of A SecuritiesMaintainedBuyBuy
Apr 1, 2025NeedhamMaintainedBuyBuy
Mar 12, 2025GuggenheimReiteratedBuyBuy
Feb 26, 2025GuggenheimReiteratedBuyBuy
Feb 26, 2025NeedhamReiteratedBuyBuy
Feb 24, 2025BTIGReiteratedBuyBuy
Feb 11, 2025NeedhamReiteratedBuyBuy
Dec 24, 2024BTIGReiteratedBuyBuy
Dec 20, 2024Goldman SachsInitiated—Buy
Nov 6, 2024Cantor FitzgeraldReiterated—Overweight
Nov 6, 2024NeedhamReiteratedBuyBuy
Sep 10, 2024MizuhoMaintainedOutperformOutperform
Sep 4, 2024B of A SecuritiesMaintainedBuyBuy
Sep 3, 2024Leerink PartnersMaintainedOutperformOutperform
Sep 3, 2024JefferiesMaintainedBuyBuy
Sep 3, 2024NeedhamMaintainedBuyBuy